IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab
出版年份 2014 全文链接
标题
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume 73, Issue 9, Pages 1595-1597
出版商
BMJ
发表日期
2014-05-16
DOI
10.1136/annrheumdis-2013-205002
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
- (2014) Jun Hashimoto et al. Modern Rheumatology
- Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
- (2013) T. Koike et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan
- (2012) Shumpei Yokota et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
- (2012) P Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?
- (2012) Yoshiya Tanaka ANNALS OF THE RHEUMATIC DISEASES
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
- (2012) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis
- (2012) Yoshiya Tanaka CURRENT OPINION IN RHEUMATOLOGY
- The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
- (2012) Josef S. Smolen et al. Nature Reviews Rheumatology
- Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
- (2012) V. Strand et al. RHEUMATOLOGY
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
- (2011) D. T. Felson et al. ANNALS OF THE RHEUMATIC DISEASES
- Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
- (2011) T. Koike et al. ANNALS OF THE RHEUMATIC DISEASES
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatoid arthritis
- (2010) David L Scott et al. LANCET
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment
- (2009) S Nishida et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
- (2008) N Nishimoto et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now